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Abstract  
  
In the treatment of inflammatory bowel diseases, the use of azathioprine is increasing over the time. It has 
been demonstrated that the effectiveness of this therapy is modulated by the metabolism of aza- thioprine, 
which is mainly exerted by both thiopurine methyl-transferase and inosine triphosphatase enzymes. 
Several studies reported chromatographic methods to determine the amount of its metabo- lites in 
erythrocytes, but there are not reported methods to dose them in peripheral blood mononuclear cells 
(PBMCs). The development of a method capable to quantify azathioprine nucleoside metabolites in this 
compartment could give better information on drug penetration and metabolism in the active site. In this 
work, we validated a new chromatographic method suitable for the monitoring of the two major 
biologically active ribonucleos(t)ide metabolites of azathioprine in PBMCs: 6-thioguanosine and 6-methyl-
mercaptopurine riboside. After PBMCs extraction from blood through separation on density gradient, 
samples underwent a de-phosphorylation procedure with acid phosphatase (only one aliquot for each 
sample) and were then treated with a protein precipitation protocol in acetonitrile, followed by UPLC-
tandem-mass spectrometry analysis. The calibration curve for each metabolite in PBMC fitted a least 
squares model (weighed 1/X) from 0.048 to 25 ng (r2 = 0.998). 
Both accuracy and precision parameters fitted FDA guidelines. We tested this method by monitoring the 
concentrations of each metabolite in PBMC from eight inflammatory bowel diseases affected patients, 
receiving azathioprine maintenance therapy with optimal results. 
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1. Introduction 
 
Azathioprine (AZA), a purine analogue, is currently used for the treatment of inflammatory-bowel-diseases 
(IBD), particularly to handle cases refractory to first-level management. Despite the ben- efits from this 
therapy, there is a great inter-individual variability in the effectiveness and in the onset of adverse events 
related to the treatment, which occurs in up to 20% of treated patients. In particular, the most common 
problems concerning this therapy are represented by relapses, medullar suppression, hepatic toxicity and 
pancreatitis [1]. Current studies suggest that differences in the drug metabolism, caused by genetic 
differences [2,3], are responsible for the different response to the treatment [1,2,4]. Once inside the cell, 
AZA is converted in 6-mercapto-purine (6-MP) by glutathione- S-transferase and undergoes several 
metabolic transformations that lead to the production of two different active nucleosides: 6-thioguanosine 
(6-TG) and 6-methyl-mercaptopurine riboside (6- MMPr) [4]. These metabolites have some differences in 
their effect on target cells: the current opinion is that 6-TG should be respon- sible for the 
immunosuppressive effect, while 6-MMPr should be a secondary metabolism product (dependent by TPMT 
activity) with a less effective action, but a stronger toxic effect on the liver [1]. So, an overproduction of 6-
TG could lead to medullar sup- pression (excessive effect), instead, an overproduction of 6-MMPr could 
lead to hepatic toxicity. The decision to undertake the treat- ment with azathioprine is currently based on 
the administration of scalar doses of this drug (with an initial dose of 50–100 mg daily), evaluating the 
clinical response: the decrease of symptoms without toxic effects will lead to the maintenance of the treat- 
ment, while the lack of efficacy or the occurrence of severe adverse events will lead to discontinuation of 
the therapy. High perfor- mance liquid chromatography (HPLC) methods were previously developed to 
quantify azathioprine metabolites levels in erythro- cytes, in order to assess the 6-TG/6-MMPr in these cells 
[5–9]. The common opinion is that the monitoring of these metabolites concentrations could be useful to 
the treatment personalization [10–12]. However, there is not a concentration cut-off value univo- cally 
acknowledged, and the therapeutic drug monitoring is not performed on target cells: lymphocytes and 
monocytes. To our knowledge, to date there is just one method capable to quantify 6-thioguanosine and 6-
metylmercaptopurine riboside only in lym- phoblasts [13]. Furthermore, this method was developed for the 
quantification of these metabolites after intravenous infusion of 6-mercaptopurine (leading to a greater 
exposure and concentra- tions), for the treatment of acute lymphoblastic leukaemia. 
In this study we modified and improved a procedure previ- ously developed for the extraction of another 
nucleoside analogue (ribavirin) from PBMCs and erythrocytes [14,15] and we developed a new UPLC-
MS/MS method for the quantification of these two metabolites. Moreover, the resulting method has been 
validated according to FDA guidelines [16] and tested for its eligibility for laboratory use by the 
quantification of eight real-life specimens. 
 
2. Materials and methods 
 
2.1. Chemicals 
Acetonitrile HPLC grade and methanol HPLC grade were purchased from J.T. Baker (Deventer, Holland). 
HPLC grade water was produced with Milli-DI system coupled with a Synergy 185 system by Millipore 
(Milan, Italy). Blank PBMC sample were taken from blood of healthy donors, kindly supplied by the Blood 
Bank of the Maria Vittoria Hospital (Turin, Italy). 6-Thioguanosine,      6-methyl-mercaptopurine      riboside, 
5∗-amino-deoxy-thymidine    (5∗     amino-deoxy-T),    dl-dithiotreitol (DTT)  and  acid  phosphatase  type  4  
from  sweet  potato  were purchased from Sigma-Aldrich Corp (Milan, Italy). The phosphatase enzyme was 
stored in a refrigerator at 4 ◦C to prevent degradation. Analytes structures are reported in Fig. 1. 
 
2.2. UPLC instruments and chromatographic conditions 
 
The chromatographic analyses were performed with a Waters Acquity UPLC system, with a binary pump, a 
refrigerated sample manager and a TQD detector (Waters, Milan, Italy). Chromatographic separation was 
performed by an Acquity UPLC HSS T3 1.8 µ,m, column (150 mm × 2.1 mm, Waters, Milan, Italy), protected 
by a pre-column frit (0.2 µ,m, 2.1 mm, Waters, Milan, Italy) at 40 ◦C using the column thermostat. Capillary 
voltage was set to 1.5 kV. Mass transitions were monitored at 242.3 > 116.1, 300.0 > 168.0 and 299.1 > 
167.0 for 5∗amino-deoxy-T, 6-TG and 6-MMPr, respectively. Collision ener- gies were 20 eV (5∗amino-
deoxy-T), 15 eV (6-TG), and 18 eV (6-MMPr), with a cone voltage of 20 V for all molecules. Desolvation 
temperature was set to 450 ◦C, with a source temperature of 150 ◦C. Desolvation gas (nitrogen) was 
produced by a Parker NitroFlowLab: desolvation and cone flow were 800 and 50 L/h, respectively. Collision 
gas was Argon. The run was performed with a gra- dient (Table 1) of two mobile phases: mobile phase A 
(H2O with formic acid 0.05%) and mobile phase B (acetonitrile with formic acid 0.05%). 
 
2.3. Stock solutions, standards and quality controls 
 
Stock solutions of 6-TG and 6-MMPr were made in NH4OH 1 M and methanol, respectively, with a final 
concentration of 1 mg/mL, and stored at −20 ◦C until use, no longer than 1 month. 
Calibrating solutions were initially prepared at scalar con- centration in pure water, and then used, at the 
time of each analysis, to spike blank aliquots of PBMC (suspended in 500 µ,L of water:methanol 30:70 v/v), 
in order to obtain eight standard samples (STDs) and three quality controls (QCs). 
The amounts of both compounds in the eight standard samples were, in progress: 0.048 ng, 0.097 ng, 0.194 
ng, 0.388 ng, 0.775 ng, 3.125 ng, 6.25 ng, 25 ng. Similarly, three quality controls (QCs), High, Medium and 
Low were prepared, starting from the same PBMC aliquots. Amounts of 6-TG and 6-MMPr for QC-H, QC-M 
and QC-L were 20 ng, 0.624 ng and 0.0776 ng, respectively. 
Internal Standard (IS) was prepared by diluting 50 µ,L of a stock solution of 5∗amino-5∗deoxy-thymidine (1 
mg/mL) in 4 mL of a solu- tion  of  water–methanol  50:50. 
STDs, QCs were immediately used, while patients’ samples were stored at −80 ◦C until analyses. 
 
2.4. PBMC preparation procedure 
 
PBMC from patients were extracted from blood (about 12 mL) through a separation on density gradient 
with two CPT tubes. After the separation (15 min, 1600 × g, 20 ◦C) the PBMC portion was transferred in a 
new falcon tube of 50 mL and washed with 
40 mL of NaCl 0.9%. After this washing step, supernatant was dis- carded and pellet was added with 2 mL of 
ammonium salts solution (ammonium chloride and ammonium carbonate 7 and 0.072 g/L, respectively) 
and incubated for 1 min at room temperature, in order to eliminate eventually remaining erythrocytes. 
Then, 38 mL of NaCl 0.9% was added and 500 µ,L of the resulting cell suspen- sion was transferred in a 
beaker and put in a Bekman Coulter Z2 (Instrumentation Laboratory, Milan, Italy), managed by Z2 Accu- 
Comp Software (Version 3.01) for the cell count, as previously described [14,17–19]. This counting method 
is eligible for the cor- rect determination of the number and volume of PBMCs, evidencing moreover the 
absence of erythrocytes. 
After a new centrifugation, supernatant was discarded and cell pellet was resuspended in 1 mL of 
H2O/methanol (30:70 v/v) and frozen at −80 ◦C. 
Blank PBMC from healthy donors were extracted from buffy- coat with a similar procedure: the only 
difference consisted in the use of a initial separation with Ficoll (Lynphoprep®) as previously described   
[14,17–19]. 
 
2.5. Specificity and selectivity 
 
Interference from endogenous compounds was investigated by the analysis of six different blank PBMC 
samples. 
 
2.6. Enzyme digestion and extraction procedure 
 
Each aliquot of PBMC of 2 × 106  cells from healthy donors was divided into two aliquots (so obtaining two 
aliquots of 1 × 106 cells) and then spiked with calibrating solutions, in order to obtain STDs and QCs. Then, 
these aliquots were spiked with 40 µ,L of IS solution. Real samples underwent the same process, but they 
were added with 100 µ,L of pure water, to obtain the same volume of STDs and QCs. 
After this step, each sample was centrifuged at 6800 × g for 5 min at 4 ◦C, and the supernatant was 
transferred in a new PTFE tube; 200 µ,L of methanol were added to each resulting pellet, then vortexed 5 s 
and centrifuged again at 20,000 × g for 5 min at 4 ◦C. 
Supernatants were added to the corresponding PTFE tube and then dried in vacuum centrifuge at 60 ◦C for 
approximately 1 h. 
Resulting dry pellets were resuspended in 200 µ,L of a mixture of water, Tris–HCl pH 8 and sodium acetate 
buffer 1 M pH 4 (in pro- portions of 10:30:2.5 v/v/v, respectively). Only one aliquot of each sample was 
spiked with 0.5 units of acid phosphatase, to convert phosphorylated metabolites to the unphosphorylated 
form, leaving the other one untreated. 
So, this procedure resulted in the production of two different calibration curves and two series of QCs: one 
treated and the other one untreated. 
All samples were incubated for 1 h and then added with 20 µ,L of a solution 0.4 M of DTT, 1 mL of 
acetonitrile, vortex-mixed 10 s and, finally, centrifuged 20,000 × g for 10 min (without brake) at 4 ◦C to 
achieve protein precipitation. Supernatants were transferred again in glass shots and dried at 60 ◦C in 
vacuum centrifuge (around 1.5 h). 
Resulting dry extracts were finally dissolved in 100 µ,L of pure water and 7.5 µ,L have been injected in the 
chromatographic sys- tem. 
 
2.7. Accuracy, precision, and limit of quantification 
 
Intra-day and inter-day accuracy and precision of the method were determined by assaying in six validation 
sessions, with double-replicate PBMC samples of all 6-TG/6-MMPr QCs, treated and untreated. Accuracy 
was calculated as the mean percent devi- ation from the nominal concentration. Inter-day and intra-day 
precisions were expressed as the standard percent deviation at each QC concentration. The calibration 
curve was based on the eight calibration points described above. 
Limit of detection (LOD) in PBMC was defined as the concen- tration that yields a signal-to-noise ratio of 3. 
Percent deviation from the nominal concentration (measure of accuracy) and rela- tive standard deviation 
(measure of precision) of the concentration considered as the limit of quantification (LOQ) had to be <20%, 
as requested by FDA guidelines. 
 
2.8. Recovery and matrix effect 
 
Average recovery of 6-TG and 6-MMPr was determined by com- paring the peak height of the extracts from 
the spiked QC samples (20 ng, 0.624 ng and 0.078 ng) with those obtained by direct injec- tion of the same 
amount of drug in presence of DTT (the same amount as in the extracted samples). The recovery 
determination was performed both for treated and untreated samples. 
Evaluation of matrix effect was performed comparing peak heights corresponding to unextracted spiked 
solutions (the same used for recovery determination) with those corresponding to dry extracts of blank 
PBMC samples, resuspended with the same spiked solutions, according to Taylor et al. [20]. The same 
procedure was repeated also on extracts from 2 and 4 millions of cells to compare eventual differences 
accounted by the cell number. 
 
 
2.9. Stability assessment 
 
The stability of samples stored at −80 ◦C was evaluated compar- ing the quantified amounts of each 
metabolite in QC samples at 2, 3 and 4 weeks of conservation, with the same QCs stored at −80 ◦C and 
freshly prepared (in triple replicate). “Freeze and Thaw” stabil- ity was assessed analyzing High and Low 
QCs after three cycles of thawing and comparing the corresponding amounts. 
Stock solution stability was evaluated comparing the peak areas obtained from the direct injection of a 
diluted solution (50 ng/mL in water) prepared from the stock stored at −20 ◦C for 2 months with another 
one, at the same theoretical concentration, obtained from a freshly prepared stock. 
 
2.10. Patients recruiting and Intra-PBMC concentration calculation 
 
The method was tested on samples from eight patients, all in maintenance treatment with AZA, after 
informed consent was given. All patients have been diagnosed with inflammatory bowel disease (Crohn’s 
disease or Ulcerative Colitis) and have been previously genotyped for TPMT rs1800460 and rs1142345 poly- 
morphisms. 
Blood sampling at the end of dosing interval (Ctrough) was per- formed after written informed consent 
given. 
Once the amounts of 6-TG and 6-MMPr were obtained in each aliquot, the concentrations were calculated 
correcting amounts on the basis of PBMC volumes, through the formula: M/(N◦ × MCV), where M is the 
amount of each molecule, N◦ and MCV were the number and mean cell volume of PBMCs, determined with 
the cell coulter [15,17–19]. 
This calculation has been done for both treated and untreated patients’ samples. 
 
3. Results 
 
3.1. Sensibility and specificity 
 
A typical chromatogram for the highest amount of 6-TG and 6-MMPr in phosphatase-digested and un-
digested PBMC sam- ples is shown in Fig. 2  while  IS  peaks  are  reported  in  Fig.  3. No consistent 
differences in retention times  between  treated and untreated samples have been observed. Peaks 
representing 5’amino-5∗deoxythymidine, 6-TG and 6-MMPr were observed at retention  times  of  1.97 ± 
0.02,  3.23 ± 0.01  and  4.75 ± 0.01 min, respectively. No interfering peaks generated from endogenous sub- 
stances were observed on the chromatograms for “blank” PBMCs. LOQ and LOD were 0.0488 and 0.0244 
ng, respectively, for both analytes (Figs. 4 and 5A and B). 
 
3.2. Accuracy, precision, and limit of quantification 
 
Relative standard error for intra- and inter-day assay precision were determined by six different validation 
sessions. Results of method validation are shown in Table 2. 
Calibration curves fitted a least squares model (weighed 1/X) in the range from 0.0488 to 25 ng, with a 
mean regression coefficient r2 of 0.998. 
 
3.3. Recovery and matrix effect 
 
Mean recoveries for 6-TG and 6-MMPr in treated samples were 107% and 105% respectively, resulting 
stable among different QC levels (SD 4% and 6%, respectively). 
In untreated samples, mean recoveries changed to 101% and 77% for 6-TG and 6-MMPr, respectively (SD 
among different QCs 14% and 6%, respectively). Mean recovery for IS was 98% with SD of 5% in treated 
samples, and 93% with SD of 7% in untreated samples. 
Mean matrix effect in treated samples was +10% and +14% (SD among different QCs 8% and 5%) for 6-TG 
and 6-MMPr, respectively; in untreated samples, matrix effect was −7% and −9% (SD among different QCs 
14% and 5%) for 6-TG and 6-MMPr, respectively. 
Matrix effect did not result influenced by cell number: the mean difference in signals obtained in extracts 
from aliquots of 2 and 4 million cells, compared with the standard 2 millions cells aliquots, was only 2 and 
3%, respectively. 
 
3.4. Stability 
 
Stock solution did not show a degradation after 1 month of storage at −20 ◦C (+3% deviation from freshly 
prepared stock solution). “Freeze and Thaw” and −80 ◦C stability data observed at High and Low QC levels 
are fully reported in Table 3. 6-TG and 6-MMPr resulted stable at −80 ◦C for 5 weeks and were not 
consistently degraded for up to three freezing and thawing cycles. 
 
3.5. Analysis of samples from patients 
 
The median number of extracted PBMCs and MCV were 1,108,380 (inter-quartile range, IQR. 419,650–
1,954,330) and 305 fL (IQR 292–322 fL). Median concentrations of total 6-TG and 6- MMPr were 375 ng/mL 
(IQR 212–1357 ng/mL) and 709 ng/mL (IQR 95–1520 ng/mL), respectively. Only one sample had 
undetectable 6-MMPr intracellular concentration. The un-phosphorylated frac- tion of 6-TG and 6-MMPr 
was under the limit of quantification in 4 out of 8 and 6 out of 8 samples, respectively, evidencing that 
azathioprine metabolites are present mainly as phosphory- lated compounds (nearly 10 folds higher than 
un-phosphorylated form). 
Seven out of eight patients had homozygous wild-type (*1/*1) genotype, only one patient carried a *3A 
haplotype  (rs1800460 G>A and rs1142345 A>G): the  median  ratio  between  total  6- TG and 6-MMPr ([6-
TG]/[6-MMPr]) was 0.50 (IQR 0.18–0.53) in wild-type homozygotes, while it was 2.34 in the only 
heterozygote patient. 
 
4. Discussion 
 
In the treatment of inflammatory bowel diseases, the use of aza- thioprine is increasing over the time. It 
has been demonstrated that the effectiveness of this therapy is modulated by the metabolism of 
azathioprine, mainly by TPMT and ITPA enzymes; the evalua- tion of concentrations in biologic fluid of the 
biologically active metabolites could help clinicians in the therapy modulation. Sev- eral methods have been 
developed to determine the amount of 6-TG and 6-MMPr in erythrocytes, but up to now there were not 
methods to dose them in PBMCs. 
Our method is the first capable to successfully quantify the total concentration of 6-TG and 6-MMPr 
nucleotides and nucleosides in PBMCs from IBD affected patients, treated with AZA. 
As a whole, six validation tests were performed and, as reported, the values of precision and accuracy 
obtained for the quality con- trols during the validation sessions fit perfectly within the range of 15% 
imposed by the FDA guidelines. The value of LOQ allows a  precise  and  accurate  dosage  of  the  total  
intracellular  concen- trations of 6-TG and 6-MMPr for the majority of the real PBMC samples extracted 
with our method. With our method we observed a difference of more than 10 times between the total and 
the un- phosphorylated fraction of the two metabolites, which was often under the LOQ. The evidence of a 
strong phosphorylation of 6-TG and 6-MMPr at the active site has never been previously reported. 
However, the very low amount of nucleoside forms of 6-TG and 
6-MMPr suggests to use their determination only as a good control for the treatment with acid 
phosphatase. 
Our method successfully identified the only one patient with a low activity variant on TPMT gene, 
evidencing in this patient an extremely higher ratio between intracellular total 6-TG and 6-MMPr as 
compared with wild-type homozygotes. This is very important because it confirms evidences observed in 
red blood cells and suggests that the monitoring of metabolites intracellular con- centrations (both intra-
PBMC and intra-RBC ones) is concordant with the genetic information. 
However, further studies are needed to evaluate if this tool offers more useful information than the only 
genetic or metabolic screening of patients [21]. 
Each aliquot of  extracted  PBMC  corresponds  to  only  6 mL of blood from patients in maintenance 
therapy with AZA: the immunosuppression of these patients could explain the low mean number of PBMC 
for aliquot. 
The use of an automatic cell coulter resulted important for the correct simultaneous determination of the 
MCV and number of PBMCs, preventing issues due to inaccuracy in the cell count and to the adoption of an 
approximate MCV. So, using these data for the calculation of intracellular concentration, we adjusted the 
con- centrations of 6-TG and 6-MMI to the real cellular composition of PBMC samples. 
An interesting observed issue was the need of DTT also in unex- tracted samples (water spiked with 
metabolites) to detect the right amount of 6-TG. The absence of this issue for 6-MMPr makes us to suppose 
that the phenomenon could be due to the free-to-react thi- olic group in the 6-TG molecule (although no 
peak corresponding to by-products has been identified by full MS scan). 
Our method is based on an enzyme dependent de- phosphorylation, as that used by Dervieux et al. [13] and 
which we use in other validated methods for the quantification of phosphorylated ribavirin [14,15]. This 
procedure replaces the acid hydrolysis and the use of heat, which are required for the conversion of 
nucleosides to free bases [8,9,22]. 
The other main important difference consists in the capability of this method to discriminate the nucleoside 
(in untreated samples, very low) from the nucleotide form (much higher, in treated sam- ples) of both main 
azathioprine metabolites. However, we cannot determinate the different amounts of mono-, di- and tri-
phosphate forms of nucleotides. 
The large recovery percentages, around 100% for  both  6-TG and 6-MMPr in treated samples and for 77% 
for 6-MMPr only in untreated samples, makes us confident on a good extraction yield and on the short 
term stability of the compounds at our working conditions. Also a low matrix effect was observed: it was 
positive in treated samples (+10% and +14% for 6-TG and 6-MMPr, respectively) and negative in untreated 
samples (−7% and −9% for 6-TG and 6-MMPr, respectively), but within limits requested by FDA. Moreover, 
this effect seemed to be quite stable (the maximum standard deviation was 14% for 6-TG in untreated 
samples) between different con- centrations and not influenced by cells number. Furthermore, the chosen 
number of PBMC for standard and QCs was comparable to that in real specimens. 
Finally, in a recent work from our group [14], we observed the same phenomenon in RBV intracellular 
determination, and it was proved to be only related to the use of buffered solutions (the pH 4 sodium 
acetate buffer and the solution in which acid phosphatase is conserved). 
Both metabolites resulted stable at our storing conditions for at least 5 weeks at −80 ◦C and resistant up to 
three freezing and thawing cycles. 
Moreover, the advantages of our method, respect to others, are: the fast run (7 min); the use of an 
enzymatic dephosphorylation, avoiding the use of strong acids and high temperature; the cheap extraction 
method through protein precipitation and the adoption of a cheap internal standard. 
Finally, the use of a double calibration curve (treated and untreated), although it is cumbersome, grants a 
higher reliability of results for both treated and untreated samples. 
Possible limit consists in the two drying steps, making the extraction procedure time consuming. 
 
5. Conclusions 
 
In conclusion, this UPLC–MS/MS method results suitable for the simple, accurate and precise dosage of 
PBMC concentrations of total 6-TG and 6-MMPr. Nowadays, no published studies have investi- gated the 
correlation between 6-TG and 6-MMPr concentrations in PBMC and response/toxicity. The only markers 
already used for therapeutic drug monitoring are the concentrations of these metabolites in erythrocytes: 
however, the determination of the real number and volume of erythrocytes used for the analysis is diffi- 
cult and the measurement in erythrocytes is only a surrogate of the quantification of the active metabolites 
in the target cells. 
For these reasons, this method could give a new tool to the clin- ician to obtain the most useful information 
upon the concentration of the AZA major metabolites at the active site, allowing them to prevent relapses 
and toxic effects.  
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Fig. 1. Chemical structures of target analytes: 6-MMPr (A), 6-TG (B) and 5∗amino-5∗deoxy-thymidine (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Chromatograms corresponding to the highest standard point of the calibration curve: Parts (A) and 
(B) show the signal of 6-thioguanosine and in treated and untreated samples, respectively, and (C) and (D) 
that of 6-methyl-mercaptopurine riboside in the same samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Chromatographic peaks of 5∗-amino-5∗deoxy-thymidine in treated (A) and un-treated (B) samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Comparison between chromatographic peaks of 6-thioguanosine at the limit of quantification (upper 
line) and in the blank extracts (bottom line) if treated (A) or untreated (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Comparison between chromatographic peaks of 6-methyl-mercaptopurine riboside, at the limit of 
quantification (upper line) and in the blank extracts (bottom line) if treated (A) or untreated (B). 
 
 
 
 
 
 
 
Table 1 
Chromatographic conditions (gradient). Mobile phase A (H2 O + 0.05% formic acid) and mobile phase B 
(acetonitrile + 0.05% formic acid). 
 
 
 
 
Table 2 
Overview of intra- and interday imprecision and accuracy of the assay for the quantification of 6-
thioguanosine and 6-methylmercaptopurine-riboside in PBMC extracts: all values fit the acceptance criteria 
by FDA. 
 
 
 
 
Table 3 
Overview of the analytes stability at −80 ◦C. Stability data are referred to a comparison with fresh-prepared 
QCs and RSD (%) are referred to triple replicate data from high and low QCs levels. 
 
